Patent Application
20080153851
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. The tachykinins are distinguished by a conserved carboxyl-terminal sequence. In addition to substance P, the known mammalian tachykinins include neurokinin A and neurokinin B. The current nomenclature designates the receptors for substance P, neurokinin A, and neurokinin B as neurokinin-1 (NK-1), neurokinin-2 (NK-2), and neurokinin-3 (NK-3), respectively. Tachykinin, and in particular substance P, antagonists are useful in the treatment of clinical conditions which are characterized by the presence of an excess of tachykinin, in particular substance P, activity, including disorders of the central nervous system, nociception and pain, gastrointestinal disorders, disorders of bladder function and respiratory diseases. Attempts have been made to provide antagonists for the receptors of substance P and other tachykinin peptides in order to more effectively treat the various disorders and diseases mentioned above.
The present invention is directed to certain aminolactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
The present invention is directed to compounds of the formula I:
wherein:
Q is selected from the group consisting of:
An embodiment of the present invention includes compounds of the formula Ia:
wherein R1 is defined herein;
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds of the formula Ib:
wherein R1 is defined herein;
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds of the formula Ic:
wherein R1a, R1b and R1c are defined herein;
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds of the formula Id:
wherein R1a, R1b and R1c are defined herein;
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds wherein Q is selected from the group consisting of:
Within this embodiment the present invention includes compounds wherein Q is methyl.
An embodiment of the present invention includes compounds wherein R1 is cyclopentyl which is substituted with R1a, R1b and R1c.
An embodiment of the present invention includes compounds wherein R1 is cyclohexyl which is substituted with R1a, R1b and R1c.
An embodiment of the present invention includes compounds wherein R1a, R1b and R1c are independently selected from:
Within this embodiment the present invention includes compounds wherein two of R1a, R1b and R1c are hydrogen, and one of R1a, R1b and R1c is independently selected from:
An embodiment of the present invention includes compounds wherein R6, R7 and R8 are independently selected from the group consisting of:
(1) hydrogen, and
(2) —CF3.
Within this embodiment the present invention includes compounds wherein R6, R7 and R8 and the phenyl ring to which they are attached form a 3,5-bis(trifluoromethyl)phenyl ring.
An embodiment of the present invention includes compounds wherein R11, R12 and R13 are independently selected from the group consisting of:
Within this embodiment the present invention includes compounds wherein R11, R12 and R13 and the phenyl ring to which they are attached form a 4-fluorophenyl ring.
Specific embodiments of the present invention include a compound which is selected from the group consisting of the subject compounds of the Examples herein and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. Formula I shows the structure of the class of compounds without preferred stereochemistry. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art. Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
As appreciated by those of skill in the art, halo or halogen as used herein are intended to include fluoro, chloro, bromo and iodo. Similarly, C1-6, as in C1-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbons in a linear or branched arrangement, such that C1-6alkyl specifically includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, pentyl and hexyl. A group which is designated as being independently substituted with substituents may be independently substituted with multiple numbers of such substituents.
The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are benzenesulfonic, citric, hydrobromic, hydrochloric, maleic, fumaric, succinic and tartaric acids. It will be understood that, as used herein, references to the compounds of the present invention are meant to also include the pharmaceutically acceptable salts.
Exemplifying the invention is the use of the compounds disclosed in the Examples and herein. Specific compounds within the present invention include a compound which selected from the group consisting of the compounds disclosed in the following Examples and pharmaceutically acceptable salts thereof and individual diastereomers thereof.
The compounds of the present invention are useful in the prevention and treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of tachykinin, in particular substance P, activity. Thus, for example, an excess of tachykinin, and in particular substance P, activity is implicated in a variety of disorders of the central nervous system. Such disorders include mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders and psychotic disorders with delusions or hallucinations; delerium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; Parkinson's disease and other extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; substance-related disorders arising from the use of alcohol, amphetamines (or amphetamine-like substances), caffeine, cannabis, cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives; sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delerium, withdrawal delerium, persisting dementia, psychotic disorders, mood disorders, anxiety disorders, sexual dysfunction and sleep disorders; epilepsy; Down's syndrome; demyelinating diseases such as MS and ALS and other neuropathological disorders such as peripheral neuropathy, for example diabetic and chemotherapy-induced neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage such as cerebral infarction, subarachnoid haemorrhage or cerebral oedema.
Tachykinin, and in particular substance P, activity is also involved in nociception and pain. The compounds of the present invention will therefore be of use in the prevention or treatment of diseases and conditions in which pain predominates, including soft tissue and peripheral damage, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage; low back pain; sciatica; ankylosing spondylitis, gout; and scar pain.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, adult respiratory distress syndrome, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis. Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of neoplasms, including breast tumours, neuroganglioblastomas and small cell carcinomas such as small cell lung cancer.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of gastrointestinal (GI) disorders, including inflammatory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intercranial pressure, gastro-oesophageal reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation, heartburn, for example, episodic, nocturnal or meal-induced heartburn, and dyspepsia.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of a variety of other conditions including stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; plasma extravasation resulting from cytokine chemotherapy, disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia, frequent urination and urinary incontinence, including the prevention or treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine. The compounds of the present invention are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.
The compounds of the present invention are particularly useful in the prevention or treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. For example, the compounds of the present invention are of use optionally in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderate or highly emetogenic cancer chemotherapy, including high-dose cisplatin. Most especially, the compounds of the present invention are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents, including those routinely used in cancer chemotherapy, and emesis induced by other pharmacological agents, for example, rolipram. Examples of such chemotherapeutic agents include alkylating agents, for example, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics. Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in Nausea and Vomiting: Recent Research and Clinical Advances, Eds. J. Kucharczyk et al, CRC Press Inc., Boca Raton, Fla., USA (1991) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine, streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Treatment Reports (1984) 68(1), 163-172]. A further aspect of the present invention comprises the use of a compound of the present invention for achieving a chronobiologic (circadian rhythm phase-shifting) effect and alleviating circadian rhythm disorders in a mammal. The present invention is further directed to the use of a compound of the present invention for blocking the phase-shifting effects of light in a mammal.
The present invention is further directed to the use of a compound of the present invention or a pharmaceutically acceptable salt thereof, for enhancing or improving sleep quality as well as preventing and treating sleep disorders and sleep disturbances in a mammal. In particular, the present invention provides a method for enhancing or improving sleep quality by increasing sleep efficiency and augmenting sleep maintenance. In addition, the present invention provides a method for preventing and treating sleep disorders and sleep disturbances in a mammal which comprising the administration of a compound of the present invention or a pharmaceutically acceptable salt thereof. The present invention is useful for the treatment of sleep disorders, including Disorders of Initiating and Maintaining Sleep (insomnias) (“DIMS”) which can arise from psychophysiological causes, as a consequence of psychiatric disorders (particularly related to anxiety), from drugs and alcohol use and abuse (particularly during withdrawal stages), childhood onset DIMS, nocturnal myoclonus, fibromyalgia, muscle pain, sleep apnea and restless legs and non specific REM disturbances as seen in ageing.
The particularly preferred embodiments of the instant invention are the treatment of emesis, urinary incontinence, depression or anxiety by administration of the compounds of the present invention to a subject (human or companion animal) in need of such treatment.
The present invention is directed to a method for the manufacture of a medicament for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal comprising combining a compound of the present invention with a pharmaceutical carrier or diluent. The present invention is further directed to a method for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins in a mammal comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
The present invention also provides a method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of the present invention or a composition comprising a compound of the present invention. As used herein, the term “treatment” or “to treat” refers to the administration of the compounds of the present invention to reduce, ameliorate, or eliminate either the symptoms or underlying cause of the noted disease conditions, in a subject (human or animal) that suffers from that condition or displays clinical indicators thereof. The term “prevention” or “to prevent” refers to the administration of the compounds of the present invention to reduce, ameliorate, or eliminate the risk or likelihood of occurrence of the noted disease conditions, in a subject (human or animal) susceptible or predisposed to that condition.
The compounds of this invention are useful for antagonizing tachykinins, in particular substance P in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine and asthma in a mammal in need of such treatment. This activity can be demonstrated by the following assays.
Receptor Expression in COS: To express the cloned human neurokinin-1 receptor (NK1R) transiently in COS, the cDNA for the human NK1R was cloned into the expression vector pCDM9 which was derived from pCDM8 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site. Transfection of 20 ug of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 ul of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM KH2PO4, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF using the IBI GENEZAPPER (IBI, New Haven, Conn.). The cells were incubated in 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin-streptomycin, and 90% DMEM media (GIBCO, Grand Island, N.Y.) in 5% CO2 at 37° C. for three days before the assay.
Stable Expression in CHO: To establish a stable cell line expressing the cloned human NK1R, the cDNA was subcloned into the vector pRcCMV (INVITROGEN). Transfection of 20 ug of the plasmid DNA into CHO cells was achieved by electroporation in 800 ul of transfection buffer supplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI). The transfected cells were incubated in CHO media [10% fetal calf serum, 100 U/ml penicillin-streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, Kans.), 0.7 mg/ml G418 (GIBCO)] in 5% CO2 at 37° C. until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NK1R was selected for subsequent applications such as drug screening.
Assay Protocol using COS or CHO: The binding assay of human NK1R expressed in either COS or CHO cells is based on the use of 125I-substance P (125I-Sp, from DU PONT, Boston, Mass.) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human NK1R. Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, N.J.) and resuspended in appropriate volume of the binding buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.2 mg/ml BSA, 0.01 mM phosphoramidon) such that 200 ul of the cell suspension would give rise to about 10,000 cpm of specific 125I-SP binding (approximately 50,000 to 200,000 cells). In the binding assay, 200 ul of cells were added to a tube containing 20 ul of 1.5 to 2.5 nM of 125I-SP and 20 ul of unlabeled substance P or any other test compound. The tubes were incubated at 4° C. or at room temperature for 1 hour with gentle shaking. The bound radioactivity was separated from unbound radioactivity by GF/C filter (BRANDEL, Gaithersburg, Md.) which was pre-wetted with 0.1% polyethylenimine. The filter was washed with 3 ml of wash buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl) three times and its radioactivity was determined by gamma counter. The activation of phospholipase C by NK1R may also be measured in CHO cells expressing the human NK1R by determining the accumulation of inositol monophosphate which is a degradation product of IP3. CHO cells are seeded in 12-well plate at 250,000 cells per well. After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of 3H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline. LiCl is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 37° C. for 15 min. Substance P is added to the well at final concentration of 0.3 nM to activate the human NK1R. After 30 min of incubation at 37° C., the media is removed and 0.1 N HCl is added. Each well is sonicated at 4° C. and extracted with CHCl3/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG 1×8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N formic acid. The inositol monophosphate is eluted with 0.2 M ammonium formate-0.1 N formic acid and quantitated by beta counter. In particular, the intrinsic tachykinin receptor antagonist activities of the compounds of the present invention may be demonstrated by these assays. The compounds of the following examples have activity in the aforementioned assays in the range of 0.05 nM to 10 □M. The activity of the present compounds may also be demonstrated by the assay disclosed by Lei, et al., British J. Pharmacol., 105, 261-262 (1992).
According to a further or alternative aspect, the present invention provides a compound of the present invention for use as a composition that may be administered to a subject in need of a reduction of the amount of tachykinin or substance P in their body.
The term “composition” as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. In general, pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Oily suspensions may be formulated by suspending the active ingredient in a suitable oil. Oil-in-water emulsions may also be employed. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
Pharmaceutical compositions of the present compounds may be in the form of a sterile injectable aqueous or oleagenous suspension. The compounds of the present invention may also be administered in the form of suppositories for rectal administration. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention may be employed. The compounds of the present invention may also be formulated for administered by inhalation. The compounds of the present invention may also be administered by a transdermal patch by methods known in the art.
The compositions containing compounds of the present invention may be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. The term “unit dosage form” is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples in the pharmacy arts of unit dosage forms. The compositions containing compounds of the present invention may also be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient. Such kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The terms “administration of” or “administering a” compound should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individuals body in a therapeutically useful form and therapeutically effective amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories. The term “therapeutically effective amount” refers to a sufficient quantity of the compounds of the present invention, in a suitable composition, and in a suitable dosage form to treat or prevent the noted disease conditions.
The compounds of the present invention may be administered in combination with another substance that has a complimentary effect to the tachykinin and substance P inhibitors of the present invention. Accordingly, in the prevention or treatment of emesis, a compound of the present invention may be used in conjunction with other anti-emetic agents, especially 5HT3 receptor antagonists, such as ondansetron, granisetron, tropisetron, palenosetron and zatisetron, a corticosteroid, such as dexamethasone, or GABAB receptor agonists, such as baclofen. Likewise, for the prevention or treatment of migraine a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5HT1 agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), α-adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, 5-HT1A agonists or antagonists, especially 5-HT1A partial agonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof. For the treatment or prevention of eating disorders, including obesity, bulimia nervosa and compulsive eating disorders, a compound of the present invention may be used in conjunction with other anorectic agents. It will be appreciated that for the treatment or prevention of pain or nociception or inflammatory diseases, a compound of the present invention may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent.
It will be appreciated that when using any combination described herein, both the compound of the present invention and the other active agent(s) will be administered to a patient, within a reasonable period of time. The compounds may be in the same pharmaceutically acceptable carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers such as conventional oral dosage forms which are taken simultaneously. The term “combination” also refers to the case where the compounds are provided in separate dosage forms and are administered sequentially. Therefore, by way of example, one active component may be administered as a tablet and then, within a reasonable period of time, the second active component may be administered either as an oral dosage form such as a tablet or a fast-dissolving oral dosage form. By a “fast dissolving oral formulation” is meant, an oral delivery form which when placed on the tongue of a patient, dissolves within about 10 seconds. By “reasonable period of time” is meant a time period that is not in excess of about 1 hour. That is, for example, if the first active component is provided as a tablet, then within one hour, the second active component should be administered, either in the same type of dosage form, or another dosage form which provides effective delivery of the medicament.
The compounds of this invention may be administered to patients (humans and animals, including companion animals, such as dogs, cats and horses) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician.
In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level of the compounds of the present invention, or pharmaceutically acceptable salts thereof, is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day. The dosage range will generally be about 0.5 to 1000 mg per patient per day, which may be administered in single or multiple doses. Preferably, the dosage range will be about 0.5 mg to 500 mg per patient per day; more preferably about 0.5 mg to 200 mg per patient per day; and even more preferably about 5 mg to 50 mg per patient per day. Specific dosages of the compounds of the present invention, or pharmaceutically acceptable salts thereof, for administration include 1 mg, 5 mg, 10 mg, 30 mg, 100 mg, and 500 mg. Pharmaceutical compositions of the present invention may be provided in a formulation comprising about 0.5 mg to 1000 mg active ingredient; more preferably comprising about 0.5 mg to 500 mg active ingredient; or 0.5 mg to 250 mg active ingredient; or 1 mg to 100 mg active ingredient. Specific pharmaceutical compositions for treatment or prevention of excess tachykinins comprise about 1 mg, 5 mg, 10 mg, 30 mg, 100 mg, and 500 mg of active ingredient.
Several methods for preparing the compounds of this invention are illustrated in the following Examples. Starting materials and the requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures or as illustrated herein. All NMR spectra were obtained on instrumentation at a field strength of 400 or 500 MHz in either CDCl3 or CD3OD with reported chemical shifts as □. The HPLC/MS analyses were obtained using an Agilent 1100 Series HPLC in combination with a Waters Micromass ZQ mass spectrometer. The HPLC RP column was a Waters Exterra MS-C18 (5 □m) 3.0×50 mm column eluting with a 10-100% acetonitrile/water (both containing 0.05% TFA) gradient over 3.75 min with a run time of 5.50 min. UV monitoring was done at 210 nM. Retention times (Rt) are reported in minutes based on the MS data. The reported m/e value was usually the parent molecular ion, except when the 100% ion was not the parent ion as also indicated. Preparative chiral HPLC was done with the indicated Chiracel 25×250 mm columns eluting at 9 mL per min with the indicated percent isopropanol/heptanes solvent mixture. Retention times (Rt) are reported in minutes based on the UV chromatogram monitored at 210 or 254 nm.
To a round-bottom flask equipped with an argon-filled balloon was loaded 5.0 g (25.1 mmol) N—BOC 4-piperidone, 2.89 g sodium tert-butoxide (30.1 mmol), 0.056 g palladium acetate (0.30 mmol), and 0.183 g 2-(dicyclohexylphosphino)-2′-methylbiphenyl (0.5 mmol). 150 mL THE was added followed by the addition of 4-fluoro-1-bromobenzene. After 5 evacuation/argon cycles, the reaction was heated to 80° C. for 24 hr. After cooling to ambient temperature, the reaction mixture was quenched with a saturated (aqueous) solution of ammonium chloride, filtered through a pad of celite, and rinsed the pad with copious amounts of ethyl acetate. After separation of the layers, the organic phase was washed with brine, dried over Na2SO4, filtered, concentrated in vacuo and purified on silica gel (1-15% EtOAc/hexanes linear gradient; then 15% EtOAc/hexanes). This provided the title compound. 1H-NMR (CDCl3): □ 1.53 (s, 9H), 2.54-2.64 (m, 2H), 3.40-3.60 (m, 2H), 3.64-3.76 (m, 1H), 4.18-4.40 (m, 2H), 7.07 (dd, 2H, J=9, 9 Hz), 7.17 (dd, 2H, J=6, 9 Hz) ppm.
To a cooled (−78° C.) solution of 4.61 g (15.7 mmol) of the ketone from step A in 200 mL of diethyl ether was added a 1.0M solution of LAH (in THF). The reaction was stirred at this temperature for 7 hr at which time the reaction was quenched by the sequential addition of H2O (0.72 mL), 5N NaOH (0:72 mL) and H2O (2.16 mL). The mixture was allowed to warm to ambient temperature overnight. The reaction mixture was then filtered through a pad of celite, rinsed with copious amounts of EtOAc, concentrated in vacuo and the crude residue was purified on silica gel (eluted with a linear gradient from 10 to 40% EtOAc/hexane) which yielded the more polar trans-diastereomer. Alternatively, the crude residue could be recrystallized from 20% EtOAc/hexanes to yield the pure trans-diastereomer. 1H-NMR (CDCl3): □ 1.50 (s, 9H), 2.05-2.12 (m, 1H), 2.58-2.66 (m, 1H), 2.70-3.00 (m, 3H), 3.85 (ddd, 1H, J=5, 11, 11 Hz), 4.00-4.30 (m, 2H), 7.05-7.12 (m, 2H), 7.24-7.30 (m, 2H) ppm.
A solution of 25.82 g (100 mmol) of (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol in 200 mL dry diethyl ether under nitrogen atmosphere was cooled in an ice/water bath. Neat 3 mL (20 mmol, 0.2 equiv) DBU was added to the reaction flask then the mixture was stirred at 0° C. for ten min. Slowly 15 mL (150 mmol, 1.5 equiv.) trichloroacetonitrile was added dropwise over 15 min. The reaction was stirred at 0° C. for 2 hr. during which time it became deep yellow in color. The volatiles were removed under vacuum using a cool bath (<35° C.) to give a pale brown mobile liquid which was purified by column chromatography on silica gel (3″×10″ pad) in two batches eluting with hexanes/EtOAc (9/1) then hexanes/EtOAc (4/1). The product fractions were combined and the solvent removed under vacuum to give the title compound as a pale yellow oil. 1H-NMR (CDCl3): □: 1.74 (d, 3H, 6.5 Hz), 6.07 (q, 1H, 6.5 Hz), 7.82 (s, 1H), 7.86 (s, 2H), 8.40 (br. s, 1H) ppm.
To a cooled (−5° C.) solution of 9.0 g of the trans-racemic alcohol (30.05 mmol) from Step B in a 2:1 mixture of cyclohexane-1,2-dichloroethane (360 mL) was added 24.53 g of the (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl-2,2,2-trichloroethanimidoate (61.0 mmol) followed by the addition 54% (in diethyl ether) HBF4 (0.5 mL). After 18 hr, an additional 0.5 mL HBF4 was added and the reaction was maintained at −5° C. for an additional 6 hr at which time the reaction mixture was diluted EtOAc. The organics were washed with a saturated solution of NaHCO3, brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel (eluted using a linear gradient of 1 to 15% EtOAc/hexanes). This provided of the desired diastereomer and the starting alcohol. 1H-NMR (CDCl3): □ 1.35 (d, 3H, J=7 Hz), 1.50 (s, 9H), 1.56-1.64 (m, 1H), 2.16-2.24 (m, 1H), 2.66-2.90 (m, 3H), 3.39 (ddd, 1H, J=5, 11, 11 Hz), 3.90-4.40 (m, 2H), 4.54 (q, 1H, J=7 Hz), 6.92 (dd, 2H. J=9, 9 Hz), 7.01 (dd, 2H, J=6, 9 Hz), 7.30 (s, 2H), 7.73 (s, 1H) ppm.
To a solution of 2.5 g of N—BOC protected piperidine obtained from Step C (4.66 mmol) in 10 mL EtOAc was added a saturated solution HCl (in EtOAc). The solution was allowed to stand for 3 hr at which time the volatiles were removed in vacuo. The crude salt was triturated with diethyl ether to high purity. To obtain the free-base form, the HCl salt was suspended in DCM and treated with a saturated solution of NaHCO3. The aqueous layer was extracted with DCM. The combined organic layer was dried over Na2SO4, filtered, concentrated in vacuo, and the crude residue was purified on silica gel (eluted with 10% methanol/DCM) which provided the free-base form of the title compound (3S,4S)-4-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)piperidine). 1H-NMR (CD3OD): □ 1.29 (d, 3H, J=7 Hz), 1.53 (dddd, 1H, J=5, 13, 13, 13 Hz), 2.30-2.37 (m, 1H), 2.55-2.70 (m, 3H), 2.90-2.95 (m, 1H), 3.47 (ddd, 1H, J=5, 11, 11 Hz), 4.69 (q, 1H, J=7 Hz), 6.84 (dd, 2H, J=9, 9 Hz), 7.03 (dd, 2H, J=6, 9 Hz), 7.41 (s, 2H), 7.73 (s, 1H) ppm.
Starting with 0.10 g of the racemic mixture of the intermediate (3S,4S)-4-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)piperidine) of step 1D (0.23 mmol), 0.028 g 1,3-cyclopentanedione (0.28 mmol) and 0.005 g p-toluenesulfonic acid were added and dissolved in 5 mL toluene. The reaction mixture was heated to reflux. After cooling, the mixture was quenched with a saturated (aqueous) solution of NaHCO3. The aqueous layer was extracted several times with DCM. The volatiles were removed in vacuo and the crude residue was purified on silica gel (eluted with 10% methanol/DCM). The enantiomers were separated by chiral HPLC using CHIRACEL AS column eluting with hexanes/EtOH (8/2) to afford the first eluting isomer (E1) and the second eluting isomer (E2). MS: E1 (MH)+ 516; E2 (MH)+ 516.
The title compound was prepared from the intermediate of example 1 step D (3S,4S)-4-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)piperidine) according to the procedure utilized in example 2 step A. MS: (MH)+ 530.
1.43 g Methyl piperidine-4-carboxylate (10 mmol) was mixed with 2.01 g 2,4-dichloropyrimidine (13.5 mmol) and 3.04 g triethylamine in 50 mL methanol. The reaction was heated to 80° C. for 24 hr. The volatiles were removed in vacuo and the crude residue was purified on silica gel eluted with a linear gradient between 40-60% EtOAc/hexanes. This provided the title compound. 1H-NMR (CDCl3): □ 1.72-1.82 (m, 2H), 2.00-2.07 (m, 2H), 2.65 (tt, 1H, J=4, 11 Hz), 3.14 (ddd, 2H, J=3, 11, 14 Hz), 3.74 (s, 3H), 4.22 (bs, 2H), 6.42 (d, 1H, J=7 Hz), 8.05 (d, 1H, J=7 Hz) ppm.
The intermediate from example 11 step A (1.8 g, 7.06 mmol) was combined with 400 mg of 10% Pd/carbon and suspended in 20 mL methanol. This flask was equipped with a hydrogen-filled balloon fitted onto a 3-way stopcock. After several evacuation/hydrogen flush cycles, the reaction mixture was stirred under 1 atm of hydrogen for 2 hr. The mixture was filtered through a pad of celite and the pad was rinsed with copious amounts of methanol. The volatiles were removed in vacuo and the crude solid was triturated to high purity with diethyl ether. This provided the title compound. 1H-NMR (CDCl3): □ 1.90-2.00 (m, 1H), 2.13 (dd, 1H, J=2, 11 Hz), 2.78 (dddd, 1H, J=5, 5, 9, 9 Hz), 3.48 (dd, 2H, J=11, 11 Hz), 3.74 (s, 3H), 3.90-4.20 (m, 1H), 4.60-5.0 (m, 1H), 6.89 (d, 1H, J=8 Hz), 8.24 *d, 1H, J=8 Hz), 8.62 (s, 1H).
The intermediate obtained from example 11 step B (825 mg, 3.75 mmol) was dissolved 10 mL DCM and the solution was cooled to −78° C. followed by the slow-dropwise addition of a 1.0M solution of DIBAL-H (in toluene). After 20 minutes, the solution was warmed to 0° C. which was maintained for 2 hr. The reaction was then quenched with an aqueous solution of NaHCO3 and stirred for 2 hr. The reaction mixture was filtered through a pad of celite and rinsed with copious amounts of DCM. The organic mixture was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel and eluted with EtOAc. This provided 180 mg of the title compound. 1H-NMR (CDCl3): □ 1.71 (dddd, 2H, J=5, 10, 10, 14 Hz), 2.05 (dddd, 2H, J=4, 4, 4, 14 Hz), 2.61 (dddd, 1H, J=5, 5, 10, 10 Hz), 3.23 (ddd, 2H, J=3, 10, 13 Hz), 4.26 (d, 2H, J=13 Hz), 6.54 (d, 1H, J=6 Hz), 8.23 (d, 1H, J=6 Hz), 8.63 (s, 1H), 9.74 (s, 1H) ppm.
The free-base form of the intermediate in example 1 step E (106 mg, 0.2442 mmol) was combined with 55 mg the intermediate obtained form example 11 step C (0.3053 mmol) in 5 mL THF followed by the dropwise addition of 97 mg of titanium(IV)isopropoxide (0.10 mmol) according to the general procedure described in example 10 step A. This provided the title compound. 1H-NMR (CD3OD): □ 1.34 (d, 3H, J=7 Hz), 1.34-1.50 (m, 1H), 2.00-2.20 (m, 2H), 2.32-2.42 (m, 1H), 2.64 (bd, 1H, J=12 Hz), 3.08-3.30 (m, 5H), 3.37 (bt, 1H, J=8 Hz), 3.66-3.74 (m, 1H), 3.82 (bd, 1H, J=12 Hz), 4.28 (d, 1H, J=14 Hz), 4.73 (q, 1H, J=7 Hz), 5.17 (d, 1H, J=14 Hz), 6.94 (dd, 2H, J=9, 9 Hz), 7.10-7.20 (m, 3H), 7.43 (s, 2H), 7.78 (s, 1H), 8.15 (dd, 1H, J=2, 8 Hz), 8.66 (s, 1H) ppm. MS: (MH)+ 611.
Trans-4-aminocyclohexanol (2.2 g, 19.1 mmol), 0.xxxg of N′-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (xxxmmol) and xxxg of p-toluenesulfonic acid. The reagents were dissolved in 15 mL of toluene and heated to 112° C. for 24 hr. Upon cooling to ambient temperature, a white precipitate formed which was collected on a fritted funnel and washed with copious amounts of (1:1) toluene/hexanes. Trans-4-aminocyclohexanol (2.2 g, 19.1 mmol) was reacted under the general protocol described in example 4 step B. This provided the title compound. 1H-NMR (CD3OD): □ 1.48 (dddd, 2H, J=4, 4, 14, 14 Hz), 1.86 (dddd, 2H, J=4, 4, 13, 13 Hz), 2.04-2.20 (m, 4H), 3.68 (dddd, 1H, J=4, 4, 11, 11 Hz), 4.24 (dddd, 1H, J=4, 4, 12, 12 Hz) 8.61 (s, 2H) ppm.
The intermediate obtained in example 4 step A (500 mg, 2.994 mmol) was dissolved in 20 mL DCM and treated with 1.53 g of Dess-Martin periodinane (3.593 mmol). After 3 hr, the volatiles were removed in vacuo and the crude residue was purified on silica gel and eluted with 1-10% Methanol/DCM (gradient elution). This provided the title compound. 1H-NMR (CDCl3): □ 2.20-2.32 (m, 2H), 2.50-2.70 (m, 6H), 4.64 (dddd, 1H, J=3, 3, 12, 12 Hz), 8.32 (s, 2H) ppm.
The free-base form of the intermediate in example 1 step E (100 mg, 0.2312 mmol) was combined with 42 mg of tert-butyl 4-(4H-1,2,4-triazol-4-yl)cyclohexanone (0.2554 mmol) in 5 mL 1,2-dichloroethane followed by the sequential addition of a drop of acetic acid and 98 mg sodium triacetoxyborohydride (0.4624 mmol). The reaction was quenched with a saturated solution of NaHCO3. After 20 min, the aqueous layer was extracted several times with EtOAc. The combined organic layers were washed with brine and dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel plates and eluted with 5% methanol/DCM several times. The faster moving component was identified as the cis-isomer and the slower moving component was identified as the trans-isomer. 1H-NMR (CD3OD) for cis-isomer: □ 1.29 (d, 3H J=7 Hz), 1.50-1.82 (m, 5H), 1.88-1.98 (m, 2H), 2.10-2.20 (m, 2H), 2.22-2.36 (m, 3H), 2.38-2.44 (m, 1H), 2.83 (ddd, 1H, J=4, 4, 12 Hz), 2.95 (ddd, 1H, J=8, 8, 12 Hz), 3.14-3.24 (m, 2H), 3.32-3.40 (m, 2H), 4.36 (dddd, 1H, J=4, 4, 8, 8 Hz), 4.70 (q, 1H, J=7 Hz), 6.86 (dd, 2H, J=9, 9 Hz), 7.05 (dd, 2H, J=6, 9 Hz), 7.41 (s, 2H), 7.74 (s, 1H), 8.67 (2H) ppm. MS: (MH)+ 585. 1H-NMR (CD3OD) for trans-isomer: J =Hz), 1.52 (dddd, 2H, J=3, 3, 13, 13 Hz), 1.67 (dddd, 1H, J=4, 4, 11, 11 Hz), 1.80 (dddd, 2H, J=4, 4, 12, 12 Hz), 2.05 (dddd, 2H, J=3, 3, 13, 13 Hz), 2.20 (bd, 2H, J=13 Hz), 2.39 (bt, 2H, J=11 Hz), 2.44 (dd, 1H, J=3, 13 Hz), 2.55 (dddd, 1H, J=3, 3, 12, 12 Hz), 2.78-2.90 (m, 2H), 3.08 (bd, 1H, J=11 Hz), 4.18 (dddd, 1H, J=4, 4, 12, 12 Hz), 4.70 (q, 1H, J=7 Hz), 6.86 (dd, 2H, J=9, 9 Hz), 7.07 (dd, 2H, J=6, 9 Hz), 7.42 (s, 2H), 7.74 (s, 1H), 8.58 (s, 2H) ppm. MS: (MH)+ 585.
To a 0° C. solution of 4.3 mL diisopropylamine in 40 mL diethyl ether was added 16 mL of a 2M solution of n-BuLi (in cyclopentane). After 30 minutes, the freshly prepared solution of LDA was transferred via cannula to a solution of 5 g 5-bromopyrimidine (31 mmol) and 4.9 g of 1,4-dioxaspiro[4.5]decan-8-one (31 mmol) in 40 mL diethyl ether at −10° C. After 2 hr, the reaction mixture was quenched with 250 mL of a 4:1 mixture of water/2N HCl. The aqueous layer was extracted several times with diethyl ether. The combined organic fractions were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel and eluted with 10-50% EtOAc/hexanes (gradient elution). This provided the title compound.
The intermediate obtained in example 5 step A (150 mg, 0.47 mmol) was dissolved in 1 mL acetonitrile and heated to 70° C. at which time a solution of ceric ammonium nitrate (644 mg, 1.20 mmol) in 2 mL H2O. The brown color discharged in 2 minutes at which time the reaction was poured into H2O. The aqueous mixture was extracted several times with diethyl ether. The combined organic fractions were dried over Na2SO4, filtered, and concentrated in vacuo. This provided the title compound.
The HCl form of the intermediate in example 1 step E (40 mg, 0.0.08 mmol) was suspended in 2 mL 1,2-dichloroethane followed by the addition of 52 mg diisopropyl ethylamine (0.40 mmol). After several minutes, 34 mg of the intermediate of example 5 step B (0.12 mmol) and 34 mg sodium triacetoxyborohydride (0.0.16 mmol) were added. The reaction was stirred for 2 days at which time a saturated solution of NaHCO3 was added. After 20 min, the aqueous layer was extracted several times with EtOAc. The combined organic layers were washed with brine and dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel plates and eluted with 5% methanol/DCM several times. The faster moving component was called D1 and the slower moving component was called D2.
The intermediate from example 5 step C (D1) (10 mg, 7.06 mmol) was combined with 2 mg of 10% Pd/carbon and suspended in 1 mL methanol and triethylamine (7.8 mg, 0.08 mmol). The reaction was carried out as described for example 11 step B. This provided the title compound.
The intermediate from example 5 step C (D2) (10 mg, 7.06 mmol) was combined with 2 mg of 10% Pd/carbon and suspended in 1 mL methanol and triethylamine (7.8 mg, 0.08 mmol). The reaction was carried out as described for example 11 step B. This provided the title compound.
The HCl form of the intermediate in example 1 step E (72 mg, 0.1529 mmol) in 2.5 mL 1,2-dichloroethane was treated with 98.8 mg diisopropylethylamine (0.7645 mmol). After 5 minutes, 35 mg of tert-butyl [(1S)-3-oxocyclopentyl]carbamate (0.1759 mmol) and 49 mg sodium triacetoxyborohydride (0.2293 mmol) were added. The reaction was quenched with a saturated solution of NaHCO3. After 20 min, the aqueous layer was extracted several times with EtOAc. The combined organic layers were washed with brine and dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel plates and eluted with 70/15/13/2 EtOAc/acetonitrile/H2O/methanol. The faster moving diastereomer was called D1 and the slower moving diastereomer was called D2. MS: D1 (MH)+ 619; D2 (MH)+ 619.
The intermediate of example 6 step A (D1) was dissolved in 2 mL EtOAc followed by the addition of an excess of a saturated solution of HCl in EtOAc. The reaction mixture was allowed to stand at ambient temperature for 3 hr at which time the volatiles were removed in vacuo. The crude salt was treated with a saturated solution of NaHCO3 and the resultant aqueous layer was extracted several times with DCM. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo and the crude residue was purified on silica gel plates and eluted with 9:1 DCM-methanol. This provided the title compound. 1H-NMR (CD3OD): □ 1.32 (d, 3H, J=7 Hz), 1.82-1.92 (m, 1H), 2.00-2.20 (m, 4H), 2.60-2.72 (m, 2H), 3.18-3.26 (m, 3H), 3.46-3.56 (m, 2H), 3.60-3.78 (m, 4H), 4.71 (q, 1H, J=7 Hz), 6.93 (dd, 2H, J=9, 9 Hz), 7.15 (dd, 2H, J=5, 9 Hz), 7.41 (s, 2H), 7.77 (s, 1H) ppm. MS: (MH)+ 519.
The intermediate of example 6 step A (D2) was reacted with HCl under the general conditions described in example 6 step B. This provided the title compound. 1H-NMR (CD3OD): □ 1.32 (d, 3H, J=7 Hz), 1.66-1.76 (m, 1H), 1.94-2.06 (m, 2H), 2.14 (ddd, 1H, J=5, 9, 15 Hz), 2.32-2.48 (m, 3H), 2.62-2.68 (m, 1H), 3.16-3.28 (m, 3H), 3.46 (ddd, 1H, J=3, 3, 9 Hz), 3.70 (ddd, 1H, J=5, 11, 11 Hz), 3.72-3.78 (m, 1H), 3.79-3.86 (m, 2H), 4.72 (q, 1H, J=7 Hz), 6.93 (dd, 2H, J=9, 9 Hz), 7.17 (dd, 2H, J=6, 9 Hz), 7.41 (s, 2H), 7.77 (s, 1H) ppm. MS: (MH)+ 519.
The intermediate of example 6 step B (20 mg, 0.0385 mmol) was combined with N′-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (22 mg, 0.1541 mmol) and dissolved in 1.5 mL pyridine. 10 mg Trimethylsilyl chloride was added and the reaction mixture was heated to 95° C. for 3 hr. After cooling to ambient temperature, the volatiles were removed in vacuo and the crude oil was purified on silica plates (10% methanol/DCM). This furnished the title compound. 1H-NMR (CD3OD): □ 1.32 (d, 3H, J=7 Hz), 1.66-1.76 (m, 1H), 1.78-2.04 (m, 4H), 2.14-2.34 (m, 3H), 2.36-2.43 (m, 1H), 2.61 (ddd, 1H, J=7, 7, 13 Hz), 2.82-2.90 (m, 2H), 2.97-3.20 (m, 1H), 3.14-3.21 (m, 1H), 3.43 (ddd, 1H, J=5, 11, 11 Hz), 4.68-4.76 (m, 2H), 6.89 (dd, 2H, J=9, 9 Hz), 7.09 (dd, 2H, J=5, 9 Hz), 7.43 (s, 2H), 7.76 (s, 1H), 8.67 (s, 2H) ppm. MS: (MH)+ 571.
The intermediate of example 6 step C (40 mg, 0.07711 mmol) was combined with N-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (44 mg, 0.3082 mmol) and dissolved in 1.5 mL pyridine. 10 mg Trimethylsilyl chloride was added and the reaction mixture was heated to 100° C. for 15 hr. After cooling to ambient temperature, the volatiles were removed in vacuo and the crude oil was quenched with saturated NaHCO3. The aqueous layer was extracted several times with DCM. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was initially purified on silica plates (eluted with 70/10/10/10 EtOAc/acetonitrile/H2O/methanol). The semi-pure material was further purified using reverse-phase-HPLC. This furnished the title compound. 1H-NMR (CD3OD): □ 1.34 (d, 3H, J=7 Hz), 1.84-2.16 (m, 3H), 2.38-2.52 (m, 2H), 2.54-2.64 (m, 2H), 2.64-2.74 (m, 1H), 3.04-3.12 (m, 1H), 3.22 (ddd, 2H, J=13, 13, 13 Hz), 3.50-3.56 (m, 1H), 3.67 (ddd, 1H, J=5, 11, 11 Hz), 3.76-3.86 (m, 1H), 3.86-3.98 (m, 1H), 4.72 (q, 1H, J=7 Hz), 4.98 (dddd, 1H, J=7, 7, 7, 7 Hz), 6.95 (dd, 2H, J=9, 9 Hz), 7.14 (dd, 2H, J=6, 9 Hz), 7.42 (s, 2H), 7.79 (s, 1H), 8.92 (s, 2H) ppm. MS: (MH)+ 571.
The HCl form of the intermediate in example 1 step E (77 mg, 0.1628 mmol) in 3.0 mL 1,2-dichloroethane was treated with 105.0 mg diisopropylethylamine (0.8140 mmol). After 5 minutes, 37 mg of tert-butyl [(1R)-3-oxocyclopentyl]carbamate (0.1872 mmol) and 52 mg sodium triacetoxyborohydride (0.2442 mmol) were added. The reaction was quenched with a saturated solution of NaHCO3. After 20 min, the aqueous layer was extracted several times with EtOAc. The combined organic layers were washed with brine and dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified on silica gel plates and eluted with 70/15/13/2 EtOAc/acetonitrile/H2O/methanol. This provided the title compound as an inseparable mixture of diastereomers. MS: (MH)+ 619.
The intermediate of example 7 step A was reacted with HCl under the general conditions described in example 6 step B. This provided the title compound as an inseparable mixture of diastereomers. MS: (MH)+ 519.
The intermediate of example 7 step B (54 mg, 0.1040 mmol) was combined with N-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (59 mg, 0.4162 mmol) and dissolved in 2.0 mL pyridine. 13.6 mg Trimethylsilyl chloride was added and the reaction mixture was heated to 95° C. for 3 hr. After cooling to ambient temperature, the volatiles were removed in vacuo and the crude oil was quenched with saturated NaHCO3. The aqueous layer was extracted several times with DCM. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by reverse-phase-HPLC. The faster moving component was called D1 and the slower moving component was called D2. D1 MS: (MH)+ 571; D2 (MH)+ 571.
The compounds in Table 1 were synthesized using the foregoing methodology, but substituting the appropriately substituted reagent as described in the foregoing examples. The requisite starting materials were commercially available, described in the literature or readily synthesized by one skilled in the art of organic synthesis without undue experimentation.
While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US05/42202 | 11/18/2005 | WO | 00 | 5/16/2007 |
| Number | Date | Country | |
|---|---|---|---|
| 60630054 | Nov 2004 | US |
